All News

Found 324 articles

• MorphoSys AG Reports Second Quarter and First Half 2021 Results

  7/29/2021

  We regained the momentum in Monjuvi sales as we exited the second quarter and are encouraged to see that momentum continuing into Q3," said Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys.

• 

  BioSpace’s Business Report Highlights Sustained Growth and New Blood

  7/22/2021

  The life sciences is always a frenetic sector when it comes to mergers & acquisitions, initial public offerings (IPOs) and Series A announcements (not to mention B and C rounds). But during the second quarter of 2021, these companies were especially busy bees – all positive signs that the industr...

• ROME Therapeutics Expands Science Leadership in Oncology, Data Science and New Target Discovery

  7/19/2021

  ROME Therapeutics, a biotechnology company harnessing the power of the repeatome in drug development, announced key appointments to its science leadership: David Proia, Ph.D., as Vice President, Oncology; Menachem Fromer, Ph.D., as Head of Data Science; and Sarah Knutson, Ph.D., as Senior Director, Early Discovery.

• Epizyme Launches EZH2Now Testing Program with Quest Diagnostics for Relapsed or Refractory Follicular Lymphoma Patients

  6/16/2021

  Epizyme, a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, launched the EZH2Now Testing Program, an Epizyme initiative in collaboration with Quest Diagnostics, the leading provider of diagnostic information services, to provide EZH2 mutation testing for patients with relapsed or refractory follicular lymphoma.

• Constellation Pharmaceuticals Provides an Update from the Ongoing MANIFEST Study of Pelabresib

  6/11/2021

  Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), today announced that three posters relating to the MANIFEST clinical trial of pelabresib (CPI-0610) in myelofibrosis (MF) were published online in association with the European Hematology Association (EHA) annual meeting.

• Valemetostat Data at EHA Shows Promising Durable Tumor Response in Patients with Peripheral T-Cell Lymphoma and Adult T-Cell Leukemia/Lymphoma

  6/11/2021

  New data from Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) for valemetostat, a potential first-in-class specific and potent dual inhibitor of EZH1 and EZH2, showed promising and durable tumor response in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) and adult T-cell leukemia/lymphoma (ATL)

• Constellation Pharmaceuticals Presents Phase 1 Data for CPI-0209 at ASCO Annual Meeting

  6/4/2021

  Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today summarized in a poster presentation preliminary data from the ongoing Phase 1/2 trial of CPI-0209

• Cellworks CBM Clinical Study Identifies Novel Biomarkers for ATRA Benefit and Failure in AML Patients

  6/4/2021

  Personalized Therapy Biosimulation Predicts with 100% Accuracy ATRA Non-Response in AML Patients with Favorable Genomic Features

• 

  MorphoSys Pharma's Double Deal: Buys Constellation and Enters Partnership with Royalty Pharma

  6/2/2021

  MorphoSys Pharma is acquiring Constellation Pharmaceuticals for about $1.7 billion. Here's everything you need to know about this billion dollars deal.

• MorphoSys AG to Acquire Constellation Pharmaceuticals and Enter into Strategic Funding Partnership with Royalty Pharma

  6/2/2021

  MorphoSys AG (FSE:MOR) announces today that it has entered into a definitive agreement with Constellation Pharmaceuticals, Inc. (NASDAQ: CNST) whereby MorphoSys will acquire Constellation for $34.00 per share in cash, which represents a total equity value of $1.7 billion.

• MorphoSys to Acquire Constellation Pharmaceuticals

  6/2/2021

  Accelerates Growth Strategy by Adding Two Mid- to Late-Stage Product Candidates: Pelabresib (CPI-0610) and CPI-0209 Bolsters Position in Hematology-Oncology and Expands into Solid Tumors Best-in-Class Combined Discovery and Development Capabilities Accelerates Ability to Provide New Cancer Treatments to Patients MorphoSys Enters into Strategic Funding Partnership with Royalty Pharma

• Gritstone Announces Changes to Its Board of DirectorsDrs. Naiyer A. Rizvi and Shefali Agarwal Join the Board

  6/1/2021

  Gritstone bio, Inc., a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, announced changes to its Board of Directors.

• Constellation Pharmaceuticals to Participate in Jefferies Virtual Healthcare Conference - May 31, 2021

  5/31/2021

  Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, announced that the Company will participate in an upcoming virtual investor conference.

• Epizyme to Participate in Jefferies Virtual Healthcare Conference - May 25, 2021

  5/25/2021

  Epizyme, a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, announced that Robert Bazemore, President and Chief Executive Officer, will participate in a fireside chat during the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 2:30 p.m. ET.

• Epizyme Announces Preclinical and Clinical Data to be Presented in Oral and Poster Sessions at Upcoming Medical Conferences in June

  5/12/2021

  Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that new preclinical and clinical data will be presented at upcoming medical meetings in June.

• Constellation Pharmaceuticals Announces First-Quarter 2021 Financial Results and Provides Business Update

  5/10/2021

  Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, announced its first-quarter 2021 financial results.

• Epizyme Provides Business Update and Reports First Quarter 2021 Financial Results

  5/6/2021

  Epizyme, a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, provided business and portfolio updates and reported first quarter 2021 financial results.

• ORIC Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Update

  5/6/2021

  ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, reported financial results and operational updates for the quarter ended March 31, 2021.

• Epizyme Announces Date of First Quarter 2021 Financial Results

  4/29/2021

  Epizyme , (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that management will host a conference call and webcast to discuss its first quarter 2021 financial results and provide a business update on Thursday, May 6, 2021 at 7:30 a.m. ET.

• Constellation Pharmaceuticals to Host Conference Call to Discuss First Quarter 2021 Results

  4/27/2021

  Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a conference call at 8:00 AM EDT on May 10, 2021, to discuss its first quarter 2021 results and provide a business update.